New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:46 EDTKPTIKaryopharm announces initiation of Selinexor Phase 2 study
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
10:04 EDTKPTIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTKPTIKaryopharm initiates clinical study of Selinexor
Subscribe for More Information
07:26 EDTKPTIKaryopharm sees existing cash, cash equivalents to fund R&D into 2H17
Karyopharm expects to end 2014 with greater than $200M in cash and cash equivalents.
07:26 EDTKPTIKaryopharm reports Q3 EPS (61c), consensus (52c)
Subscribe for More Information
07:18 EDTKPTIKaryopharm upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use